By pharmacological intervention with IL-1βR antagonist or NLRP3 inhibitor, cardiac arrhythmias were ameliorated, which indicated that activation of NLRP3 inflammasome was implicated in diabetic cardiomyopathy [91]. The gene discussed is NLRP3; the disease is cardiac arrhythmia.